ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Paris, Île-de-France, FRA:

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations....

Enrolling
Metastatic Uveal Melanoma
Drug: DYP688

Phase 1, Phase 2

Novartis
Novartis

Paris, France and 10 other locations

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Paris, France and 24 other locations

ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph ...

Active, not recruiting
Advanced Melanoma
Combination Product: LTX-315 in combination with pembrolizumab

Phase 2

Lytix Biopharma

Paris, France and 9 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp
Drug: Tebentafusp with Pembrolizumab

Phase 2, Phase 3

Immunocore
Immunocore

Paris, France and 70 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Paris, France and 45 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Villejuif, France and 227 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Paris Cedex 10, Paris, France and 154 other locations

Locations recently updated

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Paris, France and 18 other locations

of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...

Enrolling
Melanoma (Skin)
Metastatic Melanoma
Drug: Ipilimumab
Drug: Pembrolizumab

Phase 1, Phase 2

Anaveon

Paris, France and 24 other locations

the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma...

Active, not recruiting
Melanoma
Procedure: Tissue Biopsies
Drug: BO-112 plus pembrolizumab

Phase 2

Highlight Therapeutics

Paris, France and 18 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems